6678 Techno Medica Co., Ltd. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

6678

TSE Standard

Techno Medica Co., Ltd.

2,151

JPY

+71

(+3.41%)

Dec 12, 3:30 pm JST

13.80

USD

Dec 12, 1:30 am EST

Result

PTS

outside of trading hours

ー

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2022	9,699	1,861	1,851	1,281	150.9	60	May 11, 2022	J-GAAP
Mar, 2023	9,367	1,649	1,668	1,150	136.4	60	May 10, 2023	J-GAAP
Mar, 2024	10,283	1,840	1,870	1,348	173.0	68	May 9, 2024	J-GAAP
Mar, 2025	9,905	1,300	1,303	1,004	145.1	68	May 9, 2025	J-GAAP
Mar, 2026 Guidance	10,600	1,480	1,480	1,100	157.8	68	May 9, 2025	J-GAAP
YoY	+7.0%	+13.8%	+13.6%	+9.6%	+8.8%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Mar, 2021	May 13, 2020	9,200	1,000	1,000	700	49	J-GAAP
Results	May 12, 2021	9,040	1,607	1,629	1,153	51	J-GAAP
Mar, 2022	May 12, 2021	Available in future release
Results	May 11, 2022
Mar, 2023	May 11, 2022
Results	May 10, 2023
Mar, 2024	May 10, 2023
Results	May 9, 2024
Mar, 2025	May 9, 2024
Results	May 9, 2025
Mar, 2026	May 9, 2025	10,600	1,480	1,480	1,100	68	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2001	3,011	+7.1	Available in future release
Mar, 2002	3,422	+13.6
Mar, 2003	4,006	+17.1
Mar, 2004	4,462	+11.4
Mar, 2005	4,698	+5.3
Mar, 2006	5,363	+14.2
Mar, 2007	5,905	+10.1
Mar, 2008	6,668	+12.9
Mar, 2009	6,730	+0.9
Mar, 2010	7,055	+4.8
Mar, 2011	7,559	+7.1
Mar, 2012	7,980	+5.6
Mar, 2013	8,151	+2.1
Mar, 2014	9,000	+10.4
Mar, 2015	9,145	+1.6
Mar, 2016	9,032	-1.2
Mar, 2017	8,457	-6.4
Mar, 2018	8,654	+2.3
Mar, 2019	9,332	+7.8
Mar, 2020	9,810	+5.1
Mar, 2021	9,040	-7.8
Mar, 2022	9,699	+7.3
Mar, 2023	9,367	-3.4
Mar, 2024	10,283	+9.8
Mar, 2025	9,905	-3.7
Mar, 2026 Guidance	10,600	+7.0	1,480	+13.8	1,480	+13.6	157.8	+8.8

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Mar, 2024	10,283	1,840	17.9	8.93	7.31	0.56	173.0
Mar, 2025	9,905	1,300	13.1	7.12	5.68	0.56	145.1
Mar, 2026 Guidance	10,600	1,480	14.0	7.77	6.64	0.64	157.8

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	10,283	2,288	2,249	1,429	173.0
Fiscal Year	Mar, 2024	Mar, 2015	Mar, 2015	Mar, 2015	Mar, 2024

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2022	5,595	1,203	1,214	841	99.7	60	May 10, 2023	J-GAAP
Oct - Mar, 2023	6,227	1,317	1,337	972	124.7	68	May 9, 2024	J-GAAP
Oct - Mar, 2024	5,789	996	1,005	783	113.2	68	May 9, 2025	J-GAAP
Oct - Mar, 2025 Guidance	6,496	1,214	1,186	897	128.7	68	Nov 7, 2025	J-GAAP
YoY	+12.2%	+21.9%	+18.0%	+14.6%	+13.7%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Mar, 2023	1,649	732	887	-155	-505	11,750	60.43	J-GAAP
Mar, 2024	1,840	1,042	1,142	-100	-4,205	8,586	49.25	J-GAAP
Mar, 2025	1,300	945	977	-32	-470	9,061	50.51	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 2nd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Sep, 2023	4,056	523	533	376	46.2	28.5	Nov 7, 2023	J-GAAP
Apr - Sep, 2024	4,116	304	298	221	32.1	22.9	Nov 7, 2024	J-GAAP
Apr - Sep, 2025	4,104	266	294	203	29.3	19.9	Nov 7, 2025	J-GAAP
YoY	-0.3%	-12.5%	-1.3%	-8.1%	-8.6%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2023	2,368	405	404	270	33.5	17.1	Feb 7, 2024	J-GAAP
Jan - Mar, 2024	3,859	912	933	702	90.1	23.6	May 9, 2024	J-GAAP
Apr - Jun, 2024	1,999	250	255	173	25.1	12.5	Aug 7, 2024	J-GAAP
Jul - Sep, 2024	2,117	54	43	48	7.0	2.6	Nov 7, 2024	J-GAAP
Oct - Dec, 2024	2,331	280	291	205	29.7	12.0	Feb 5, 2025	J-GAAP
Jan - Mar, 2025	3,458	716	714	578	83.5	20.7	May 9, 2025	J-GAAP
Apr - Jun, 2025	1,757	-2	23	16	2.4	-0.1	Aug 6, 2025	J-GAAP
Jul - Sep, 2025	2,347	268	271	187	27.0	11.4	Nov 7, 2025	J-GAAP
YoY	+10.9%	+396.3%	+530.2%	+289.6%	+287.9%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2020	2,140	-3.2	Available in future release
Jan - Mar, 2021	3,199	+10.5
Apr - Jun, 2021	2,014	+20.0
Jul - Sep, 2021	2,277	+12.6
Oct - Dec, 2021	2,117	-1.1
Jan - Mar, 2022	3,291	+2.9
Apr - Jun, 2022	1,786	-11.3
Jul - Sep, 2022	1,986	-12.8
Oct - Dec, 2022	2,289	+8.1
Jan - Mar, 2023	3,306	+0.5
Apr - Jun, 2023	1,770	-0.9
Jul - Sep, 2023	2,286	+15.1
Oct - Dec, 2023	2,368	+3.5
Jan - Mar, 2024	3,859	+16.7
Apr - Jun, 2024	1,999	+12.9
Jul - Sep, 2024	2,117	-7.4
Oct - Dec, 2024	2,331	-1.6
Jan - Mar, 2025	3,458	-10.4
Apr - Jun, 2025	1,757	-12.1
Jul - Sep, 2025	2,347	+10.9	268	+396.3	271	+530.2	27.0	+285.7

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	3,859	994	954	702	90.1
Fiscal Year	Mar, 2024	Mar, 2015	Mar, 2015	Mar, 2024	Mar, 2024

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Mar, 2023	1,933.89	84.3	19,443	16,386	14,890	ー	May 10, 2023	J-GAAP
Mar, 2024	1,998.92	79.3	17,433	13,818	15,730	ー	May 9, 2024	J-GAAP
Mar, 2025	2,076.86	80.2	17,938	14,389	16,265	ー	May 9, 2025	J-GAAP
Apr - Sep, 2025	ー	85.5	16,558	14,149	15,997	ー	Nov 7, 2025	J-GAAP

Techno Medica Co., Ltd.(6678) Financial Results